LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers. Its precision targeted neoliposomal technology platform provides local delivery of chemotherapy for the treatment of multiple tumor types. LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is about to launch Phase 2b development. The Company’s pipeline includes multiple orphan indications such as upper tract urothelial carcinoma, stage II/III ovarian cancer and mesothelioma.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 325 Sharon Park Dr,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.lipaconcology.com/
- HQ
- Menlo Park, California
Lipac Oncology, Inc. Questions
Lipac Oncology, Inc.'s website is https://www.lipaconcology.com/
Lipac Oncology, Inc.'s LinkedIn profile is https://www.linkedin.com/company/lipac-oncology
Lipac Oncology, Inc. has
5 employees.
View email and phone details for 5
employees at Lipac Oncology, Inc..
Lipac Oncology, Inc.'s industry is
Biotechnology Research
Lipac Oncology, Inc.'s top competitors are
Bryologyx,
Trust,
Revision Therapeutics, Inc.,
Tesorx Pharma, Llc,
Summit Therapeutics, Inc.,
Tvax Biomedical, Inc.,
Foc- Fibre Optical Components Gmbh,
Crafton Biotechnology Co., Ltd.,
Lixte Biotechnology Holdings, Inc.,
Amplexd Therapeutics.
Lipac Oncology, Inc.'s categories are Biotechnology Research
Lipac Oncology, Inc.'s founding year is 2016
